ZEMURON SOLUTION

Valsts: Kanāda

Valoda: angļu

Klimata pārmaiņas: Health Canada

Aktīvā sastāvdaļa:

ROCURONIUM BROMIDE

Pieejams no:

MERCK CANADA INC

ATĶ kods:

M03AC09

SNN (starptautisko nepatentēto nosaukumu):

ROCURONIUM BROMIDE

Deva:

10MG

Zāļu forma:

SOLUTION

Kompozīcija:

ROCURONIUM BROMIDE 10MG

Ievadīšanas:

INTRAVENOUS

Vienības iepakojumā:

10X5ML

Receptes veids:

Prescription

Ārstniecības joma:

NEUROMUSCULAR BLOCKING AGENTS

Produktu pārskats:

Active ingredient group (AIG) number: 0126317001; AHFS:

Autorizācija statuss:

CANCELLED POST MARKET

Autorizācija datums:

2018-02-05

Produkta apraksts

_ _
_Page 1 of 35_
PRODUCT MONOGRAPH
ZEMURON
®
Rocuronium Bromide
10 mg/mL Solution for Injection
_ _
Non-depolarizing Skeletal Neuromuscular Blocking Agent
MERCK CANADA INC.
Date of Revision:
16750 route Transcanadienne
November 5, 2018
Kirkland, QC Canada H9H 4M7
www.merck.ca
Submission Control No: 220017
_ _
_ _
_ _
_ _
_Page 2 of 35_
_ _
TABLE OF CONTENTS
[To create the table of contents, select from the
PART I: HEALTH PROFESSIONAL INFORMATION
..........................................................3
SUMMARY PRODUCT INFORMATION
...............................................................................
3
INDICATIONS AND CLINICAL USE
.....................................................................................
3
CONTRAINDICATIONS
..........................................................................................................
4
WARNINGS AND PRECAUTIONS
.........................................................................................
4
ADVERSE REACTIONS
...........................................................................................................
8
DRUG INTERACTIONS
.........................................................................................................
12
DOSAGE AND ADMINISTRATION
.....................................................................................
13
OVERDOSAGE
.......................................................................................................................
18
ACTION AND CLINICAL PHARMACOLOGY
................................................................... 18
STORAGE AND STABILITY
.................................................................................................
26
SPECIAL HANDLING INSTRUCTIONS
..............................................................................
26
DOSAGE FORMS, COMPOSITION AND PACKAGING
.................................................... 26
PART II: SCIENTIFIC INFORMATION
...............................................................................28
PHARMACEUTI